Table 4: Compare the mean of NCV in treated patients with sodium valproate by type of nerves.
|
Type of nerves |
Drugs |
Mean |
P -value |
|
Median
|
sodium valproate in baseline |
53.4 |
0.003
|
|
Control |
58.7 |
||
|
Median
|
sodium valproate in baseline |
53.4 |
0.072
|
|
sodium valproate six month late |
53.3 |
||
|
Ulnar
|
sodium valproate in baseline |
50.1 |
0.0002
|
|
Control |
50.8 |
||
|
Ulnar
|
sodium valproate in baseline |
50.1 |
0.068
|
|
sodium valproate six month late |
50.08 |
||
|
Sural
|
sodium valproate in Baseline |
47.5 |
0.004
|
|
Control |
50.6 |
||
|
Sural
|
sodium valproate in baseline |
47.5 |
0.1
|
|
sodium valproate six month late |
47.8 |
||
|
Peroneal
|
sodium valproate in baseline |
46.8 |
0.046
|
|
Control |
46.4 |
||
|
Peroneal |
sodium valproate in baseline |
46.8 |
0.095 |
|
sodium valproate six month late |
46.75 |